



Operations Optimized

PROBLEMS SOLVED

- Patient Recruitment
- Site Engagement

SUMMARY

Infinity used DrugDev technology to keep their trial top of mind at sites and to inspire recruitment activities. This consistent engagement and motivation resulted in a significant increase in the number of patients enrolled, even during the holiday season.

“DrugDev has transformed the way we work with sites. The system has enabled us to increase collaboration and enrollment performance while streamlining timelines by replacing outdated manual processes with modern and intuitive site-friendly tools.”

- John Keilty, Vice President, Informatics at Infinity Pharmaceuticals

CASE STUDY: Infinity Pharmaceuticals

30-day Challenges Inspire Sites to Exceed Enrollment Goals for Phase II Oncology Study

CHALLENGE

Infinity Pharmaceuticals, an innovative company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases, experienced lagging enrollment on an international Phase II oncology study with a hard-to-recruit patient population. As the end-of-year holidays approached, Infinity feared that enrollment would suffer even further, incurring costly delays.

SOLUTION

Infinity implemented the DrugDev platform as a novel strategy to positively impact patient recruitment through site engagement best practices. As part of the solution, the companies worked closely together to initiate a 30-day enrollment challenge across all sites in the program using DrugDev’s Site Engagement solution including complementary features such as News, Leaderboard and Badging.

Directory News FAQ Documents VT Checklist Training Visit Guide

We're 40% Enrolled

Tags: Enrollment
Posted By: Susan Sloan
Posted: Sun, Jan 6 at 7:51 PM

Dear Study Team,

Through the end of January we've screened 592 patients and randomized 479. This means we are 40% of the way towards our goal of 1200 randomized patients.

80% of all sites activated at least a month contributed to our 479 randomized patients. Congratulations to our investigators, coordinators, pharmacists and other team members.

Below the break are other statistics you may find interesting.

Meet one of the trial's top enrolling sites, Dr Ozols and team

Tags: Best Practices, Site Spotlight
Posted By: Charlene Lee
Posted: Sun, Jan 6 at 7:34 PM


Current Rank	Site	Country	Total Randomized	Randomized This Month	Activation Date	Previous Chart Position
1	Site 22 (Dr. Dabrowski) Krakow Specialized Hospital	Poland	42	6	12/08/11	1
2	Site 18 (Dr. Laurent) Montreal Heart Institute	Canada	21	1	12/6/11	2
3	Site 14 (Dr. Forrester) Kentucky Cardiology Associates	United States	13	3	1/11/12	3
4	+1 Site 16 (Dr. Mircea) Bucharest Emergency Hospital	Romania	12	2	1/17/12	5



At the beginning of the challenge, each site was assigned a quantifiable goal for screening and enrollment. The dedicated DrugDev Site Engagement team increased communication through the newsfeed, deployed daily Leaderboards to recognize sites progressing fastest to their goals, and awarded virtual Badges as sites achieved certain milestones (e.g. enrolling their first patient during the contest period). Badge notifications were shared to all sites via the global newsfeed, with the intent of incenting other sites to improve performance, earn Badges of their own, and climb the enrollment contest Leaderboard. These activities supplemented the document management, site training, and visit guides already implemented for the Infinity study.

BENEFITS

The results of the 30-day challenge were obvious, immediate and persistent. Infinity enjoyed a tremendous boost in enrollment in December despite their initial concerns that recruiting would suffer due to the holidays. During the following six months, average enrollment remained significantly elevated as compared to the months that followed the initial recruitment period. When enrollment began to dip again in August 2012 as the trial neared its close, Infinity and DrugDev decided to repeat the 30-day contest, which once again spiked to generate impressive results.



“Infinity is very pleased to have a technology that is user friendly and quickly adopted by sites, and which allows our study team members to develop and quickly implement engagement tactics.

In addition, we appreciate the flexibility and excellent support provided by the DrugDev team.”

- Dee Rodriguez, Vice President, Clinical Operations at Infinity Pharmaceuticals

About DrugDev

The DrugDev clinical operations suite is the industry’s most comprehensive unified solutions platform – comprised of innovative technology and expert services proven to add value on thousands of clinical trials. From planning through closeout, our solutions are rigorously tested and improved by sponsors, CROs and sites of all sizes, in more than 60 countries. Through this experience we have established and integrated best practices into every feature of our system. That’s why 9 of the top 10 pharmas, 4 of the top 5 CROs, and the biggest industry collaborations are among the many organizations that trust DrugDev technology.

To learn more, request a demo at www.drugdev.com

Begin a Conversation

To learn how DrugDev can help improve your next trial from study startup to closeout, request a personal demo at www.drudev.com.